Linrodostat

Linrodostat
Clinical data
Other names	BMS-986205; ONO 7701
Routes of; administration	Oral
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2R)-N-(4-Chlorophenyl)-2-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide;
CAS Number	1923833-60-6 ;
DrugBank	DB14986 ;
ChemSpider	58828674 ;
UNII	0A7729F42K ;
Chemical and physical data
Formula	C24H24ClFN2O
Molar mass	410.92 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H];
	InChI InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1; Key:KRTIYQIPSAGSBP-ZACQAIPSSA-N;

Last updated January 01, 2026

Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.^[1]

Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).^[2]^[3]

Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, melanoma, liver cancer, non-small cell lung cancer, and solid tumors.^[4]

References

↑ "Linrodostat". NCI Drug Dictionary. National Cancer Institute.
↑ Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT (March 2021). "Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor". Molecular Cancer Therapeutics. 20 (3): 467–476. doi: 10.1158/1535-7163.MCT-20-0251 . PMID 33298590. S2CID 228087398.
↑ "IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types". onclive.com. October 31, 2019.
↑ "Linrodostat". Adis Insight. Springer Nature Switzerland AG.

External links

Fraunhoffer KJ, Delmonte AJ, Beutner GL, Bultman MS, Camacho K, Cohen B, et al. (2019). "Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor". Organic Process Research & Development. 23 (11): 2482–2498. doi:10.1021/acs.oprd.9b00359. S2CID 208690975.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Linrodostat". NCI Drug Dictionary. National Cancer Institute.

[2] Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT (March 2021). "Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor". Molecular Cancer Therapeutics. 20 (3): 467–476. doi: 10.1158/1535-7163.MCT-20-0251 . PMID 33298590. S2CID 228087398.

[3] "IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types". onclive.com. October 31, 2019.

[4] "Linrodostat". Adis Insight. Springer Nature Switzerland AG.

[1]

[2]

[3]

[4]

Clinical data

Other names	BMS-986205; ONO 7701
Routes of administration	Oral
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2R)-N-(4-Chlorophenyl)-2-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
CAS Number	1923833-60-6
DrugBank	DB14986
ChemSpider	58828674
UNII	0A7729F42K
Chemical and physical data
Formula	C₂₄H₂₄ClFN₂O
Molar mass	410.92 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H]
InChI InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1 Key:KRTIYQIPSAGSBP-ZACQAIPSSA-N